Does Gadolinium Deposition Lead to Metabolite Alteration in the Dentate Nucleus? An MRS Study in Patients with MS

References

1. 1.↵
   1. Mahad DH,
   2. Trapp BD,
   3. Lassmann H

   . Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol 2015;14:183–93 doi:10.1016/S1474-4422(14)70256-X pmid:25772897

   CrossRefPubMed
2. 2.↵
   1. Polman CH,
   2. Reingold SC,
   3. Banwell B, et al

   . Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292–302 doi:10.1002/ana.22366 pmid:21387374

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Kanda T,
   2. Ishii K,
   3. Kawaguchi H, et al

   . High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 2014;270:834–41 doi:10.1148/radiol.13131669 pmid:24475844

   CrossRefPubMed
4. 4.↵
   1. Roccatagliata L,
   2. Vuolo L,
   3. Bonzano L, et al

   . Multiple sclerosis: hyperintense dentate nucleus on unenhanced T1-weighted MR images is associated with the secondary progressive subtype. Radiology 2009;251:503–10 doi:10.1148/radiol.2511081269 pmid:19401576

   CrossRefPubMed
5. 5.↵
   1. Dekkers IA,
   2. Roos R,
   3. van der Molen AJ

   . Gadolinium retention after administration of contrast agents based on linear chelators and the recommendations of the European Medicines Agency. Eur Radiol 2018;28:1579–84 doi:10.1007/s00330-017-5065-8 pmid:29063255

   CrossRefPubMed
6. 6.↵
   1. Guo BJ,
   2. Yang ZL,
   3. Zhang LJ

   . Gadolinium deposition in brain: current scientific evidence and future perspectives. Front Mol Neurosci 2018;11:335 doi:10.3389/fnmol.2018.00335 pmid:30294259

   CrossRefPubMed
7. 7.↵
   1. Cao Y,
   2. Huang DQ,
   3. Shih G, et al

   . Signal change in the dentate nucleus on T1-weighted MR images after multiple administrations of gadopentetate dimeglumine versus gadobutrol. AJR Am J Roentgenol 2016;206:414–19 doi:10.2214/AJR.15.15327 pmid:26700156

   CrossRefPubMed
8. 8.↵
   1. Ozturk K,
   2. Nascene D

   . Effect of at least 10 serial gadobutrol administrations on brain signal intensity ratios on T1-weighted MRI in children: a matched case-control study. AJR Am J Roentgenol 2021;217:753–60 doi:10.2214/AJR.20.24536 pmid:33112200

   CrossRefPubMed
9. 9.↵
   1. Splendiani A,
   2. Corridore A,
   3. Torlone S, et al

   . Visible T1-hyperintensity of the dentate nucleus after multiple administrations of macrocyclic gadolinium-based contrast agents: yes or no? Insights Imaging 2019;10:1–10 doi:10.1186/s13244-019-0767-x pmid:31482392

   CrossRefPubMed
10. 10.↵
    1. Hu HH,
    2. Pokorney A,
    3. Towbin RB, et al

    . Increased signal intensities in the dentate nucleus and globus pallidus on unenhanced T1-weighted images: evidence in children undergoing multiple gadolinium MRI exams. Pediatr Radiol 2016;46:1590–98 doi:10.1007/s00247-016-3646-3 pmid:27282825

    CrossRefPubMed
11. 11.↵
    1. Flood TF,
    2. Stence NV,
    3. Maloney JA, et al

    . Pediatric brain: repeated exposure to linear gadolinium-based contrast material is associated with increased signal intensity at unenhanced T1-weighted MR imaging. Radiology 2017;282:222–28 doi:10.1148/radiol.2016160356 pmid:27467467

    CrossRefPubMed
12. 12.↵
    1. Adin M,
    2. Kleinberg L,
    3. Vaidya D, et al

    . Hyperintense dentate nuclei on T1-weighted MRI: relation to repeat gadolinium administration. AJNR Am J Neuroradiol 2015;36:1859–65 doi:10.3174/ajnr.A4378 pmid:26294649

    Abstract/FREE Full Text
13. 13.↵
    1. Kuno H,
    2. Jara H,
    3. Buch K, et al

    . Global and regional brain assessment with quantitative MR imaging in patients with prior exposure to linear gadolinium-based contrast agents. Radiology 2017;283:195–204 doi:10.1148/radiol.2016160674 pmid:27797676

    CrossRefPubMed
14. 14.↵
    1. Zhang Y,
    2. Cao Y,
    3. Shih GL, et al

    . Extent of signal hyperintensity on unenhanced T1-weighted brain MR images after more than 35 administrations of linear gadolinium-based contrast agents. Radiology 2017;282:516–25 doi:10.1148/radiol.2016152864 pmid:27513848

    CrossRefPubMed
15. 15.↵
    1. Stojanov DA,
    2. Aracki-Trenkic A,
    3. Vojinovic S, et al

    . Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol. Eur Radiol 2016;26:807–15 doi:10.1007/s00330-015-3879-9 pmid:26105022

    CrossRefPubMed
16. 16.↵
    1. Tanaka M,
    2. Nakahara K,
    3. Kinoshita M

    . Increased signal intensity in the dentate nucleus of patients with multiple sclerosis in comparison with neuromyelitis optica spectrum disorder after multiple doses of gadolinium contrast. Eur Neurol 2016;75:195–98 doi:10.1159/000445431 pmid:27054693

    CrossRefPubMed
17. 17.↵
    1. Kanda T,
    2. Oba H,
    3. Toyoda K, et al

    . Brain gadolinium deposition after administration of gadolinium-based contrast agents. Jpn J Radiol 2016;34:3–9 doi:10.1007/s11604-015-0503-5 pmid:26608061

    CrossRefPubMed
18. 18.↵
    1. Stagg C,
    2. Rothman D

    . Magnetic Resonance Spectroscopy: Tools for Neuroscience Research and Emerging Clinical Applications. Academic Press; 2014
19. 19.↵
    1. Feng X,
    2. Xia Q,
    3. Yuan L, et al

    . Impaired mitochondrial function and oxidative stress in rat cortical neurons: implications for gadolinium-induced neurotoxicity. Neurotoxicology 2010;31:391–98 doi:10.1016/j.neuro.2010.04.003 pmid:20398695

    CrossRefPubMed
20. 20.↵
    1. Denmark D,
    2. Ruhoy I,
    3. Wittmann B, et al

    . Altered plasma mitochondrial metabolites in persistently symptomatic individuals after a GBCA-assisted MRI. Toxics 2022;10:56 doi:10.3390/toxics10020056 pmid:35202243

    CrossRefPubMed
21. 21.↵
    1. Lange T,
    2. Dydak U,
    3. Roberts T, et al

    . Pitfalls in lactate measurements at 3T. AJNR Am J Neuroradiol 2006;27:895–901 pmid:16611787

    PubMedWeb of Science
22. 22.↵
    1. McDonald RJ,
    2. McDonald JS,
    3. Kallmes DF, et al

    . Gadolinium deposition in human brain tissues after contrast-enhanced MR imaging in adult patients without intracranial abnormalities. Radiology 2017;285:546–54 doi:10.1148/radiol.2017161595 pmid:28653860

    CrossRefPubMed
23. 23.↵
    1. McDonald RJ,
    2. McDonald JS,
    3. Kallmes DF, et al

    . Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology 2015;275:772–82 doi:10.1148/radiol.15150025 pmid:25742194

    CrossRefPubMed
24. 24.↵
    1. Ariyani W,
    2. Iwasaki T,
    3. Miyazaki W, et al

    . Effects of gadolinium-based contrast agents on thyroid hormone receptor action and thyroid hormone-induced cerebellar Purkinje cell morphogenesis. Front Endocrinol (Lausanne) 2016;7:115 doi:10.3389/fendo.2016.00115 pmid:27617003

    CrossRefPubMed
25. 25.
    1. Bower DV,
    2. Richter JK,
    3. von Tengg-Kobligk H, et al

    . Gadolinium-based MRI contrast agents induce mitochondrial toxicity and cell death in human neurons, and toxicity increases with reduced kinetic stability of the agent. Invest Radiol 2019;54:453–63 pmid:31265439

    CrossRefPubMed
26. 26.↵
    1. Feng XD,
    2. Xia Q,
    3. Yuan L, et al

    . Gadolinium triggers unfolded protein responses (UPRs) in primary cultured rat cortical astrocytes via promotion of an influx of extracellular Ca 2. +. Cell Biol Toxicol 2011;27:1–12 doi:10.1007/s10565-010-9166-2 pmid:20419501

    CrossRefPubMed
27. 27.↵
    1. Mallio CA,
    2. Rovira À,
    3. Parizel PM, et al

    . Exposure to gadolinium and neurotoxicity: current status of preclinical and clinical studies. Neuroradiology 2020;62:925–34 doi:10.1007/s00234-020-02434-8 pmid:32318773

    CrossRefPubMed
28. 28.↵
    1. Bauer K,
    2. Lathrum A,
    3. Raslan O, et al

    . Do gadolinium-based contrast agents affect 18F-FDG PET/CT uptake in the dentate nucleus and the globus pallidus? A pilot study. J Nucl Med Technol 2017;45:30–33 doi:10.2967/jnmt.116.180844 pmid:27834725

    Abstract/FREE Full Text
29. 29.↵
    1. Kreider RB,
    2. Stout JR

    . Creatine in health and disease. Nutrients 2021;13:447 doi:10.3390/nu13020447 pmid:33572884

    CrossRefPubMed
30. 30.↵
    1. Schlattner U,
    2. Tokarska-Schlattner M,
    3. Wallimann T

    . Mitochondrial creatine kinase in human health and disease. Biochim Biophys Acta 2006;1762:164–80 doi:10.1016/j.bbadis.2005.09.004 pmid:16236486

    CrossRefPubMed
31. 31.↵
    1. Dienel GA

    . Brain glucose metabolism: integration of energetics with function. Physiol Rev 2019;99:949–1045 doi:10.1152/physrev.00062.2017 pmid:30565508

    CrossRefPubMed
32. 32.
    1. Chen Y,
    2. Fry BC,
    3. Layton AT

    . Modeling glucose metabolism and lactate production in the kidney. Math Biosci 2017;289:116–29 doi:10.1016/j.mbs.2017.04.008 pmid:28495544

    CrossRefPubMed
33. 33.↵
    1. Falkowska A,
    2. Gutowska I,
    3. Goschorska M, et al

    . Energy metabolism of the brain, including the cooperation between astrocytes and neurons, especially in the context of glycogen metabolism. Int J Mol Sci 2015;16:25959–81 doi:10.3390/ijms161125939 pmid:26528968

    CrossRefPubMed
34. 34.↵
    1. Edmond J,
    2. Popjak G

    . Transfer of carbon atoms from mevalonate to n-fatty acids. J Biol Chem 1974;249:66–71 pmid:4809631

    Abstract/FREE Full Text
35. 35.↵
    1. Kopito R,
    2. Murray DM,
    3. Story DL, et al

    . The shunt pathway of mevalonate metabolism in the isolated perfused rat kidney. J Biol Chem 1984;259:372–77 pmid:6706942

    Abstract/FREE Full Text
36. 36.↵
    1. Villalba H,
    2. Shah K,
    3. Albekairi TH, et al

    . Potential role of myo-inositol to improve ischemic stroke outcome in diabetic mouse. Brain Res 2018;1699:166–76 doi:10.1016/j.brainres.2018.08.028 pmid:30165043

    CrossRefPubMed
37. 37.↵
    1. Uldry M,
    2. Ibberson M,
    3. Horisberger JD, et al

    . Identification of a mammalian H+‐myo‐inositol symporter expressed predominantly in the brain. EMBO J 2001;20:4467–77 doi:10.1093/emboj/20.16.4467 pmid:11500374

    Abstract/FREE Full Text
38. 38.↵
    1. Knight LS,
    2. Piibe Q,
    3. Lambie I, et al

    . Betaine in the brain: characterization of betaine uptake, its influence on other osmolytes and its potential role in neuroprotection from osmotic stress. Neurochem Res 2017;42:3490–3503 doi:10.1007/s11064-017-2397-3 pmid:28918494

    CrossRefPubMed
39. 39.↵
    1. Videen JS,
    2. Michaelis T,
    3. Pinto P, et al

    . Human cerebral osmolytes during chronic hyponatremia: a proton magnetic resonance spectroscopy study. J Clin Invest 1995;95:788–93 doi:10.1172/JCI117728 pmid:7860762

    CrossRefPubMedWeb of Science
40. 40.↵
    1. Ray D,
    2. Cavanagh J,
    3. Nolan C, et al

    . Neurotoxic effects of gadopentetate dimeglumine: behavioral disturbance and morphology after intracerebroventricular injection in rats. AJNR Am J Neuroradiol 1996;17:365–73 pmid:8938312

    PubMed
41. 41.↵
    1. Roman-Goldstein S,
    2. Barnett P,
    3. McCormick C, et al

    . Effects of gadopentetate dimeglumine administration after osmotic blood-brain barrier disruption: toxicity and MR imaging findings. AJNR Am J Neuroradiol 1991;12:885–90 pmid:1950917

    Abstract/FREE Full Text
42. 42.↵
    1. Forslin Y,
    2. Shams S,
    3. Hashim F, et al

    . Retention of gadolinium-based contrast agents in multiple sclerosis: retrospective analysis of an 18-year longitudinal study. AJNR Am J Neuroradiol 2017;38:1311–16 doi:10.3174/ajnr.A5211 pmid:28495943

    Abstract/FREE Full Text
43. 43.↵
    1. Forslin Y,
    2. Martola J,
    3. Bergendal Å, et al

    . Gadolinium retention in the brain: an MRI relaxometry study of linear and macrocyclic gadolinium-based contrast agents in multiple sclerosis. AJNR Am J Neuroradiol 2019;40:1265–73 doi:10.3174/ajnr.A6112 pmid:31248867

    Abstract/FREE Full Text
44. 44.↵
    1. Arevalo O,
    2. Riascos R,
    3. Rabiei P, et al

    . Standardizing magnetic resonance imaging protocols, requisitions, and reports in multiple sclerosis: an update for radiologist based on 2017 Magnetic Resonance Imaging in Multiple Sclerosis and 2018 Consortium of Multiple Sclerosis Centers Consensus Guidelines. J Comput Assist Tomogr 2019;43:1–12 doi:10.1097/RCT.0000000000000767 pmid:30015803

    CrossRefPubMed